Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL-2 in autoimmune hemolytic anemia (warm AIHA or cold agglutinin disease)
2017-003363-35Phase 2Terminated
- Sponsor
- Apellis Pharmaceuticals
- Start
- Nov 2020
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegcetacoplan in warm autoimmune hemolytic anemia (wAIHA) and cold agglutinin disease (CAD) (2 cohorts), sponsored by Apellis Pharmaceuticals. Primary endpoint: Incidence and severity of treatment-emergent adverse events. Started Nov 2020; status: terminated.
02
Drugs
pegcetacoplan
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)cold agglutinin disease (CAD)
Beyond the preview
Go deeper on 2017-003363-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003363-35.